Page 21 - Pharma Companies
BPPI Q1 sales turnover up 94.21% to Rs 146.59 cr amid Covid-19 crisis
It had posted a sales turnover of Rs 75.48 crore in the corresponding first quarter of previous fiscal year, a statement by the ministry said
 "BPPI Q1 sales turnover up 94.21% to Rs 146.59 cr amid Covid-19 crisis")
Remdesivir prices may rise after Gilead gets full authorisation from USFDA
In August, Gilead filed an application with the US Food and Drug Administration (USFDA) seeking full approval for remdesivir (Veklury)
 "Remdesivir prices may rise after Gilead gets full authorisation from USFDA")
Pick-up in biosimilar launches driving Biocon's prospects; stock rises 7.8%
As US launch of Insulin addresses a large market, improved visibility for more launches will keep sentiment elevated
 "Pick-up in biosimilar launches driving Biocon's prospects; stock rises 7.8%")
Pharmacy consolidation may disrupt domestic drug market: Credit Suisse
The report says if chemists are allowed to replace doctor's prescription with a generic drug, firms with high exposure to chronic therapeutic drugs will be impacted more
 "Pharmacy consolidation may disrupt domestic drug market: Credit Suisse")
National Expert Group meets Covid-19 vaccine makers to discuss road ahead
Representatives from Serum Institute of India, Bharat Biotech, Zydus Cadila, Gennova Biopharmaceuticals and Biological E met the expert group that is chaired by NITI member Vinod K Paul
 "National Expert Group meets Covid-19 vaccine makers to discuss road ahead")
France's Sanofi SA to buy US-based Principia Biopharma for $3.7 billion
The deal will strengthen Sanofi's research capabilities in areas such as autoimmune and allergic diseases, the companies said
 "France's Sanofi SA to buy US-based Principia Biopharma for $3.7 billion")
Natco Pharma reports 14.5% decline in net profit at Rs 122 cr for Q1
The company had posted a net profit of Rs 142.8 crore for the corresponding period of the previous fiscal
 "Natco Pharma reports 14.5% decline in net profit at Rs 122 cr for Q1")
Pharma rally may lose steam as valuations factor in near term gains
Recovery in India business, traction in new launches in the US market are needed to sustain gains
 "Pharma rally may lose steam as valuations factor in near term gains")
Mankind Pharma partners with South Korea's Daewoong for Covid drug
Will conduct clincial trials on anti-parasitic drug they claim is more effective than remdesivir
 "Mankind Pharma partners with South Korea's Daewoong for Covid drug")
Ipca Labs Q1 profit jumps more than 3-folds to Rs 445.68 cr on robust sales
The company had posted a net profit of Rs 129.43 crore for the corresponding period of the previous fiscal, Ipca Labs said in a BSE filing
 "Ipca Labs Q1 profit jumps more than 3-folds to Rs 445.68 cr on robust sales")
Alkem Labs Q1 profit jumps 2-fold to Rs 423.2 cr, revenue up at Rs 2,004 cr
Consolidated revenue from operations of the company stood at Rs 2,003.49 crore for the quarter under consideration. It was Rs 1,849.50 crore for the same period a year ago, it added
 "Alkem Labs Q1 profit jumps 2-fold to Rs 423.2 cr, revenue up at Rs 2,004 cr")
CVS raises profit forecast, in talks with US to administer Covid vaccines
CVS also said it was working with laboratories to cut down the turnaround time for coronavirus test results, which had spiked in July due to a massive increase in demand for tests
 "CVS raises profit forecast, in talks with US to administer Covid vaccines")
Teva Pharmaceutical's Q2 profit tops forecast, reaffirms 2020 outlook
The company also released with Regeneron Pharmaceuticals results for advanced trials for pain medication fasinumab
 "Teva Pharmaceutical's Q2 profit tops forecast, reaffirms 2020 outlook")
Zenara Pharma receives DCGI approval to manufacture, sell Favipiravir
Zenara Pharma announced that it has received approval from the DCGI to manufacture and sell Favipiravir tablets as a treatment option for patients with mild to moderate symptoms of Covid-19.
 "Zenara Pharma receives DCGI approval to manufacture, sell Favipiravir")
Cipla witnesses 3 senior-level exits including India biz CEO Nikhil Chopra
The company's rich legacy of care and strong sense of purpose rooted in a culture of meritocracy and high performance standards have made Cipla an employer of choice for several industry leaders
 "Cipla witnesses 3 senior-level exits including India biz CEO Nikhil Chopra")
Sun Pharma posts surprise Rs 2,184 cr Q1 pre-tax loss on one-time expense
Firm's US revenue dips 33.5%; one-time loss of Rs 3,633 cr pertains to $213.3 mn pzayment by Taro, a Sun Pharma subsidiary, for settlement of anti-trust cases in the US
 "Sun Pharma posts surprise Rs 2,184 cr Q1 pre-tax loss on one-time expense")
Sun Pharma Q1 net loss at Rs 1,655.6 cr, revenue down to Rs 7,585.3 cr
The company had posted a net profit of Rs 1,387.48 crore for the corresponding period of the previous fiscal, Sun Pharma said in a BSE filing
Dr Reddy's Q1 PAT falls 13% to Rs 579 cr, revenue up by 15% to Rs 4,417 cr
Commenting on the results, co-chairman and MD, G V Prasad said "the current quarter's financial performance has been strong across all parameters
 "Dr Reddy's Q1 PAT falls 13% to Rs 579 cr, revenue up by 15% to Rs 4,417 cr")
Hetero launches generic Covid-19 drug 'Favivir' at Rs 59 per tablet
It improves treatment accessibility to a significant amount of Covid-19 patient population, which have mild to moderate symptoms,Hetero said
Jenburkt Pharma launches Covid-19 drug Favipiravir at Rs 39 per tablet
The company hopes that the easy accessibility and affordable price point of an effective treatment such as Favivent will offer Indian citizens a timely, much-needed therapeutic solution
 "Jenburkt Pharma launches Covid-19 drug Favipiravir at Rs 39 per tablet")